Question · from the living review of Atrial Fibrillation Stroke Prevention →

Is it true that net clinical benefit of anticoagulation in subclinical AF is positive?

Likely updated weekly · as of

Priors rates this Likely — 68 out of 100, updated weekly. Probably — but it is not fully settled. On the claim that net clinical benefit of anticoagulation in subclinical AF is positive, its four-agent AI review panel weighs 18 primary peer-reviewed studies.

RefutedDoubtfulUncertainLikelyEstablished
where this sits on Priors’ scale of how settled the evidence is

How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.

The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Atrial Fibrillation Stroke Prevention review.

Related Cardiovascular questions

Is it true that DOACs reduce intracranial haemorrhage versus warfarin in AF? → Is it true that DOACs reduce stroke risk versus warfarin in non-valvular AF? → Is it true that CHA2DS2-VASc predicts stroke in non-valvular AF? → Is it true that catheter ablation reduces AF recurrence versus antiarrhythmic drugs? →
Reflects the peer-reviewed evidence as of 17 July 2026 and updates as new studies land. AI can make mistakes. Not medical advice.